Helicobacter Pylori Infections Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Country and Region - Analysis and Forecast, 2025-2035
Description
Global Helicobacter Pylori Infections Market: Industry Overview
Helicobacter pylori infection, a major cause of gastritis, peptic ulcers, and gastric cancer, affects nearly half of the world’s population. The treatment landscape includes antibiotics, gastric acid-reducing agents, and adjunctive therapies aimed at complete bacterial eradication. However, increasing antimicrobial resistance has led to a surge in research for novel therapies such as microbiome-based treatments, vaccines, and tailored antibiotic regimens.
Technological advancements in polymerase chain reaction (PCR), stool antigen testing, urea breath tests, and next-generation sequencing have significantly improved diagnosis accuracy and antibiotic resistance profiling. Additionally, digital tools and AI-based predictive algorithms are enabling clinicians to select personalized treatment regimens based on local resistance data.
Market Lifecycle Stage
The global Helicobacter pylori infections market is in a transitional lifecycle stage, shifting from conventional triple therapy toward innovative, resistance-adaptive approaches. While antibiotic-based regimens remain the cornerstone of therapy, rising resistance levels have spurred the introduction of bismuth-containing quadruple therapies, adjunctive probiotics, and next-generation antibiotics.
Pharmaceutical manufacturers are increasingly exploring vaccine development, biofilm-targeted drugs, and non-antibiotic antimicrobial agents to address long-term prevention and resistance mitigation.
Additionally, the market is supported by the expansion of diagnostic infrastructure and resistance surveillance networks across the Asia-Pacific and Europe. Regulatory agencies such as the U.S. FDA and EMA are promoting antibiotic stewardship and accelerating approvals for reformulated therapies. With rising awareness and diagnostic accessibility, the market is expected to transition toward more, precision-based management.
Market Segmentation:
Segmentation 1: By Drug Class
Antibiotics
Gastric Acid Reducing Agents
Others
Antibiotics lead the market as the cornerstone of Helicobacter pylori therapy, though resistance challenges are driving the development of new combination and resistance-guided regimens. Gastric acid–reducing agents such as PPIs and H2RAs enhance antibiotic efficacy and treatment adherence, with innovations in longer-acting formulations. The “Others” category—including probiotics, bismuth compounds, and adjunctive therapies—continues to expand, supported by growing interest in microbiome-balanced and reinfection-prevention approaches.
Segmentation 2: By Route of Administration
Oral
Intravenous
Others
Oral administration dominates due to its convenience and high patient compliance, with increasing adoption of fixed-dose oral combinations. Intravenous therapy, mainly used in severe or resistant cases, maintains a steady demand within hospital settings. The “Others” segment encompasses novel delivery technologies—such as mucosal patches and targeted-release capsules—aimed at improving bioavailability and local therapeutic targeting.
Segmentation 3: By Region
North America
Europe
Asia-Pacific
Rest-of-the-World
North America leads the market with advanced diagnostics and antimicrobial stewardship efforts, while Europe follows with robust surveillance and R&D collaborations. Asia-Pacific represents the fastest-growing region, driven by high infection prevalence and expanding healthcare access. The Rest of the World, including Latin America, the Middle East, and Africa, is emerging as a potential growth zone with increasing availability of affordable diagnostics and combination treatments.
Demand – Drivers and Limitations
Demand drivers for the global Helicobacter pylori infections market:
Rising global incidence of Helicobacter pylori infections and related gastrointestinal disorders
Growing adoption of combination and sequential therapy regimens to enhance treatment efficacy and patient outcomes
Limitations for the global Helicobacter pylori infections market:
Escalating antibiotic resistance is reducing the effectiveness of existing treatment protocols
Absence of an approved vaccine and reliance on lengthy, multi-drug treatment regimens
How can this report add value to an organisation?
Product/Innovation: The report provides comprehensive insights into the evolving therapeutic and diagnostic landscape for Helicobacter pylori infections, highlighting innovations in antimicrobial development, vaccine research, and molecular testing technologies. It helps R&D teams identify future growth areas and collaboration prospects.
Growth/Marketing: By pinpointing high-prevalence regions, treatment adoption trends, and emerging diagnostic markets, the report supports strategic planning, portfolio expansion, and marketing initiatives for gastrointestinal therapeutic developers.
Competitive: Through company benchmarking, pipeline analysis, and clinical development tracking, the report enables organizations to assess innovation trajectories and competitive positioning in the global Helicobacter pylori infection market.
Key Market Players and Competitive LandscapeThis report provides a detailed competitive analysis of major participants in the global Helicobacter pylori infections market. Companies are evaluated based on therapeutic
portfolios, diagnostic innovation, market presence, and strategic alliances.
Key players include:
Cumberland Pharmaceuticals Inc.
Phathom Pharmaceuticals, Inc.
RedHill Biopharma Ltd.
TenNor Therapeutics
These companies are actively engaged in developing advanced antimicrobial combinations, next-generation diagnostics, and preventive therapies targeting Helicobacter pylori. The competitive benchmarking section highlights R&D investments, clinical trials, collaborations with academic institutions, and regulatory milestones. Company profiles detail therapeutic portfolios, clinical outcomes, partnership initiatives, and analyst perspectives—enabling stakeholders to assess market positioning and strategic opportunities in the global Helicobacter pylori infections market.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Helicobacter pylori infection, a major cause of gastritis, peptic ulcers, and gastric cancer, affects nearly half of the world’s population. The treatment landscape includes antibiotics, gastric acid-reducing agents, and adjunctive therapies aimed at complete bacterial eradication. However, increasing antimicrobial resistance has led to a surge in research for novel therapies such as microbiome-based treatments, vaccines, and tailored antibiotic regimens.
Technological advancements in polymerase chain reaction (PCR), stool antigen testing, urea breath tests, and next-generation sequencing have significantly improved diagnosis accuracy and antibiotic resistance profiling. Additionally, digital tools and AI-based predictive algorithms are enabling clinicians to select personalized treatment regimens based on local resistance data.
Market Lifecycle Stage
The global Helicobacter pylori infections market is in a transitional lifecycle stage, shifting from conventional triple therapy toward innovative, resistance-adaptive approaches. While antibiotic-based regimens remain the cornerstone of therapy, rising resistance levels have spurred the introduction of bismuth-containing quadruple therapies, adjunctive probiotics, and next-generation antibiotics.
Pharmaceutical manufacturers are increasingly exploring vaccine development, biofilm-targeted drugs, and non-antibiotic antimicrobial agents to address long-term prevention and resistance mitigation.
Additionally, the market is supported by the expansion of diagnostic infrastructure and resistance surveillance networks across the Asia-Pacific and Europe. Regulatory agencies such as the U.S. FDA and EMA are promoting antibiotic stewardship and accelerating approvals for reformulated therapies. With rising awareness and diagnostic accessibility, the market is expected to transition toward more, precision-based management.
Market Segmentation:
Segmentation 1: By Drug Class
Antibiotics
Gastric Acid Reducing Agents
Others
Antibiotics lead the market as the cornerstone of Helicobacter pylori therapy, though resistance challenges are driving the development of new combination and resistance-guided regimens. Gastric acid–reducing agents such as PPIs and H2RAs enhance antibiotic efficacy and treatment adherence, with innovations in longer-acting formulations. The “Others” category—including probiotics, bismuth compounds, and adjunctive therapies—continues to expand, supported by growing interest in microbiome-balanced and reinfection-prevention approaches.
Segmentation 2: By Route of Administration
Oral
Intravenous
Others
Oral administration dominates due to its convenience and high patient compliance, with increasing adoption of fixed-dose oral combinations. Intravenous therapy, mainly used in severe or resistant cases, maintains a steady demand within hospital settings. The “Others” segment encompasses novel delivery technologies—such as mucosal patches and targeted-release capsules—aimed at improving bioavailability and local therapeutic targeting.
Segmentation 3: By Region
North America
Europe
Asia-Pacific
Rest-of-the-World
North America leads the market with advanced diagnostics and antimicrobial stewardship efforts, while Europe follows with robust surveillance and R&D collaborations. Asia-Pacific represents the fastest-growing region, driven by high infection prevalence and expanding healthcare access. The Rest of the World, including Latin America, the Middle East, and Africa, is emerging as a potential growth zone with increasing availability of affordable diagnostics and combination treatments.
Demand – Drivers and Limitations
Demand drivers for the global Helicobacter pylori infections market:
Rising global incidence of Helicobacter pylori infections and related gastrointestinal disorders
Growing adoption of combination and sequential therapy regimens to enhance treatment efficacy and patient outcomes
Limitations for the global Helicobacter pylori infections market:
Escalating antibiotic resistance is reducing the effectiveness of existing treatment protocols
Absence of an approved vaccine and reliance on lengthy, multi-drug treatment regimens
How can this report add value to an organisation?
Product/Innovation: The report provides comprehensive insights into the evolving therapeutic and diagnostic landscape for Helicobacter pylori infections, highlighting innovations in antimicrobial development, vaccine research, and molecular testing technologies. It helps R&D teams identify future growth areas and collaboration prospects.
Growth/Marketing: By pinpointing high-prevalence regions, treatment adoption trends, and emerging diagnostic markets, the report supports strategic planning, portfolio expansion, and marketing initiatives for gastrointestinal therapeutic developers.
Competitive: Through company benchmarking, pipeline analysis, and clinical development tracking, the report enables organizations to assess innovation trajectories and competitive positioning in the global Helicobacter pylori infection market.
Key Market Players and Competitive LandscapeThis report provides a detailed competitive analysis of major participants in the global Helicobacter pylori infections market. Companies are evaluated based on therapeutic
portfolios, diagnostic innovation, market presence, and strategic alliances.
Key players include:
Cumberland Pharmaceuticals Inc.
Phathom Pharmaceuticals, Inc.
RedHill Biopharma Ltd.
TenNor Therapeutics
These companies are actively engaged in developing advanced antimicrobial combinations, next-generation diagnostics, and preventive therapies targeting Helicobacter pylori. The competitive benchmarking section highlights R&D investments, clinical trials, collaborations with academic institutions, and regulatory milestones. Company profiles detail therapeutic portfolios, clinical outcomes, partnership initiatives, and analyst perspectives—enabling stakeholders to assess market positioning and strategic opportunities in the global Helicobacter pylori infections market.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
- Executive Summary
- Scope of Study
- Definition
- Inclusion and Exclusion Criteria
- 1. Global Helicobacter Pylori Infections Market: Industry Outlook
- 1.1 Market Overview and Ecosystem
- 1.2 Epidemiological Analysis
- 1.2.1 U.S.
- 1.2.2 EU
- 1.2.2.1 Germany
- 1.2.2.2 France
- 1.2.3 Rest-of-the-World
- 1.3 Market Trends
- 1.4 Clinical Trial Analysis
- 1.5 Regulatory Landscape Analysis
- 1.5.1 Legal Requirement and Framework in U.S.
- 1.5.2 Legal Requirement and Framework in E.U.
- 1.5.3 Legal Requirement and Framework in Asia-Pacific
- 1.5.4 Legal Requirement and Framework in Rest-of-the-World
- 1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraints
- 1.6.4 Market Opportunities
- 2. Global Helicobacter Pylori Infections Market, by Drug Class, $Million, 2024-2035
- 2.1 Antibiotics
- 2.2 Gastric Acid Reducing Agents
- 2.3 Others
- 3. Global Helicobacter Pylori Infections Market, by Route of Administration, $Million, 2024-2035
- 3.1 Oral
- 3.2 Intra-Venous
- 3.3 Others
- 4. Global Helicobacter Pylori Infections Market, by Region, $Million, 2024-2035
- 4.1 North America
- 4.1.1 Key Findings
- 4.1.2 Market Dynamics
- 4.1.3 Market Sizing and Forecast
- 4.1.3.1 North America Helicobacter Pylori Infections Market (by Country)
- 4.1.3.1.1 U.S.
- 4.1.3.1.2 Canada
- 4.2 Europe
- 4.2.1 Key Findings
- 4.2.2 Market Dynamics
- 4.2.3 Market Sizing and Forecast
- 4.2.3.1 Europe Helicobacter Pylori Infections Market (by Country)
- 4.2.3.1.1 Germany
- 4.2.3.1.2 France
- 4.2.3.1.3 Italy
- 4.2.3.1.4 Spain
- 4.2.3.1.5 U.K.
- 4.2.3.1.6 Rest-of-Europe
- 4.3 Asia-Pacific
- 4.3.1 Key Findings
- 4.3.2 Market Dynamics
- 4.3.3 Market Sizing and Forecast
- 4.3.3.1 Asia-Pacific Helicobacter Pylori Infections Market (by Country)
- 4.3.3.1.1 Japan
- 4.3.3.1.2 Rest-of-Asia-Pacific
- 4.4 Rest-of-the-World
- 4.4.1 Key Findings
- 4.4.2 Market Dynamics
- 4.4.3 Market Sizing and Forecast
- 5. Global Helicobacter Pylori Infections Market: Competitive Benchmarking and Company Profiles
- 5.1 Competitive Benchmarking
- 5.2 Competitive Landscape
- 5.2.1 Key Strategies and Developments by Company
- 5.2.1.1 Funding Activities
- 5.2.1.2 Mergers and Acquisitions
- 5.2.1.3 Regulatory Approvals
- 5.2.1.4 Partnerships, Collaborations, and Business Expansions
- 5.2.2 Key Developments Analysis
- 5.3 Company Profiles
- 5.3.1 Cumberland Pharmaceuticals Inc.
- 5.3.1.1 Company Overview
- 5.3.1.2 Product Portfolio
- 5.3.1.3 Target Customers / End Users
- 5.3.1.4 Key Personnel
- 5.3.1.5 Analyst View
- 5.3.2 Phathom Pharmaceuticals, Inc.
- 5.3.2.1 Company Overview
- 5.3.2.2 Product Portfolio
- 5.3.2.3 Target Customers / End Users
- 5.3.2.4 Key Personnel
- 5.3.2.5 Analyst View
- 5.3.3 RedHill Biopharma Ltd.
- 5.3.3.1 Company Overview
- 5.3.3.2 Product Portfolio
- 5.3.3.3 Target Customers / End Users
- 5.3.3.4 Key Personnel
- 5.3.3.5 Analyst View
- 5.3.4 TenNor Therapeutics
- 5.3.4.1 Company Overview
- 5.3.4.2 Product Portfolio
- 5.3.4.3 Target Customers / End Users
- 5.3.4.4 Key Personnel
- 5.3.4.5 Analyst View
- 5.3.5 Others
- 6. Research Methodology
- List of Figures
- Figure: Helicobacter Pylori Infections Market (by Scenario), $Million, 2024, 2030, and 2035
- Figure: Global Helicobacter Pylori Infections Market, 2024 and 2035
- Figure: Global Helicobacter Pylori Infections Market Key Trends, Impact Analysis, 2024-2035
- Figure: North America Helicobacter Pylori Infections Market, $Million, 2024-2035
- Figure: Europe Helicobacter Pylori Infections Market, $Million, 2024-2035
- Figure: Asia-Pacific Helicobacter Pylori Infections Market, $Million, 2024-2035
- Figure: Rest-of-the-World Helicobacter Pylori Infections Market, $Million, 2024-2035
- List of Tables
- Table: Market Snapshot
- Table: Market Dynamics
- Table: Global Helicobacter Pylori Infections Market (by Drug Class), $Million, 2024-2035
- Table: Global Helicobacter Pylori Infections Market (by Route of Administration), $Million, 2024-2035
- Table: Global Helicobacter Pylori Infections Market (by Region), $Million, 2024-2035
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
